Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tomaras

Showing results (191-200 of 525) with videos related to

Pageof 53
Sort By:
Plos Pathogens|September 13, 2011
Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodiesBen-Jiang Ma, S Munir Alam, Eden P Go, et al.
Journal of Virology|August 6, 2010
Low-dose mucosal simian immunodeficiency virus infection restricts early replication kinetics and transmitted virus variants in rhesus monkeysJinyan Liu, Brandon F Keele, Hui Li, et al.
The Journal of Infectious Diseases|April 1, 2011
A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteersPaul Spearman, Michelle A Lally, Marnie Elizaga, et al.
Scientific Reports|March 6, 2021
In vitro and in vivo inhibition of malaria parasite infection by monoclonal antibodies against Plasmodium falciparum circumsporozoite protein (CSP)Merricka C Livingstone, Alexis A Bitzer, Alish Giri, et al.
Frontiers in Immunology|March 13, 2026
Early rise in nasal secretory IgA associated with shorter duration of SARS-CoV-2 virus shedding in an acute infection cohortCaroline Brackett, Lu Zhang, Bich T N Do, et al.
Journal of Pharmaceutical Sciences|July 27, 2019
Framework Mutations of the 10-1074 bnAb Increase Conformational Stability, Manufacturability, and Stability While Preserving Full Neutralization ActivityBruce A Kerwin, Chelsey Bennett, Yan Brodsky, et al.
Mucosal Immunology|January 10, 2013
HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-lifeN L Yates, A R Stacey, T L Nolen, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 17, 2011
HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectableStephen C De Rosa, Evan P Thomas, John Bui, et al.
Frontiers in Immunology|March 30, 2026
AS01<sub>B</sub>-, MF59-, and alum-based adjuvants and HIV vaccine immunogenicity: a <i>post-hoc</i> cross-protocol comparison of results from HVTN 100, 107, 120, and 702Ferdinando Menezes, Shiyu Chen, Nicole Grunenberg, et al.
JCI Insight|April 20, 2017
T-bet+ B cells are induced by human viral infections and dominate the HIV gp140 responseJames J Knox, Marcus Buggert, Lela Kardava, et al.
Pageof 53

Showing results (191-200 of 525) with videos related to

Sort By:
Pageof 53
Plos Pathogens|September 13, 2011
Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodiesBen-Jiang Ma, S Munir Alam, Eden P Go, et al.
Journal of Virology|August 6, 2010
Low-dose mucosal simian immunodeficiency virus infection restricts early replication kinetics and transmitted virus variants in rhesus monkeysJinyan Liu, Brandon F Keele, Hui Li, et al.
The Journal of Infectious Diseases|April 1, 2011
A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteersPaul Spearman, Michelle A Lally, Marnie Elizaga, et al.
Scientific Reports|March 6, 2021
In vitro and in vivo inhibition of malaria parasite infection by monoclonal antibodies against Plasmodium falciparum circumsporozoite protein (CSP)Merricka C Livingstone, Alexis A Bitzer, Alish Giri, et al.
Frontiers in Immunology|March 13, 2026
Early rise in nasal secretory IgA associated with shorter duration of SARS-CoV-2 virus shedding in an acute infection cohortCaroline Brackett, Lu Zhang, Bich T N Do, et al.
Journal of Pharmaceutical Sciences|July 27, 2019
Framework Mutations of the 10-1074 bnAb Increase Conformational Stability, Manufacturability, and Stability While Preserving Full Neutralization ActivityBruce A Kerwin, Chelsey Bennett, Yan Brodsky, et al.
Mucosal Immunology|January 10, 2013
HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-lifeN L Yates, A R Stacey, T L Nolen, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 17, 2011
HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectableStephen C De Rosa, Evan P Thomas, John Bui, et al.
Frontiers in Immunology|March 30, 2026
AS01<sub>B</sub>-, MF59-, and alum-based adjuvants and HIV vaccine immunogenicity: a <i>post-hoc</i> cross-protocol comparison of results from HVTN 100, 107, 120, and 702Ferdinando Menezes, Shiyu Chen, Nicole Grunenberg, et al.
JCI Insight|April 20, 2017
T-bet+ B cells are induced by human viral infections and dominate the HIV gp140 responseJames J Knox, Marcus Buggert, Lela Kardava, et al.
Pageof 53